Page last updated: 2024-12-11

dioleoyl phosphatidylethanolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dioleoyl phosphatidylethanolamine: chemical name in article is incorrect - phosphatidylethandamine instead of phosphatidylethanolamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dioleoyl phosphatidylethanolamine : A phosphatidylethanolamine in which the phosphatidyl acyl groups are both oleoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6437392
CHEBI ID60285
SCHEMBL ID3290885
MeSH IDM0249909

Synonyms (37)

Synonym
dioleoyl phosphatidylethanolamine
l-alpha-phosphatidylethanolamine, dioleoyl, >=99% (gc), >=98% (tlc), lyophilized powder
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, >=99.0% (10 mg phospholipid per ml chcl3, tlc)
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, >=98.0% (tlc)
dope
CHEBI:60285 ,
1,2-dioleoyl phosphatidylethanolamine
3-{[(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-2-[(9z)-octadec-9-enoyloxy]propyl (9z)-octadec-9-enoate
2462-63-7
dioleoylphosphatidylethanolamine
dopea
pe 18:1_18:1
pe 36:2
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate
ethanol, 2-amino-, dihydrogen phosphate (ester), monoester with 1,2-diolein
1,2-dioleoyl phosphatidyl ethanolamin
9-octadecenoic acid (9z)-, 1-((((2-aminoethoxy)hydroxyphosphinyl)oxy)methyl)-1,2-etanediyl ester
lipofectace
dioleoyl (glycerophospho)ethanolamine
dl-dope
olein, 1,2-di-, 2-aminoethyl hydrogen phosphate
1,2-di-olein 2-aminoethyl hydrogen phosphate
EPITOPE ID:136781
SCHEMBL3290885
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, >=97.0% (tlc)
mfcd16621009
l-alpha-phosphatidylethanolamine, dioleoyl
(z)-3-(((2-aminoethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate
Q27127165
1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine
(z)-3-(((2-aminoethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyldioleate
coatsome me-8181 (dope)
dioleoyl phosphatidyl ethanolamine
1,2-di-o-oleoyl-sn-glycero-3-phosphatidylethanolamine
A912198
DTXSID101300852
1,2-dioleoyl-sn-glycero-3-phospho-etha-nolamine

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The results of this study suggest that fusogenic liposomal preparation of CyA is safe and can be useful for future studies."( Safety evaluation of nanoliposomes containing cyclosporine a after ocular administration.
Abedini, E; Ashraf, H; Banaee, T; Farzadnia, M; Malaekeh-Nikouei, B; Mosallaei, N, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
"DVar7 modified acid-sensitive nanocarriers combined with acidity regulation have great potential to improve drug resistance in clinical practice, thus improving the response rate and therapeutic effect of chemotherapy."( A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer.
Du, S; Gao, H; Luo, C; Shi, J; Wang, F; Zhai, L, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"The purpose of this study was to employ a nanoscale liposomal carrier to resolve the delivery problem, and increase the bioavailability and efficiency of pTT."( Topical delivery of DNA oligonucleotide to induce p53 generation in the skin via thymidine dinucleotide (pTT)-encapsulated liposomal carrier.
Fang, YP, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphatidylethanolamineA class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxy group of ethanolamine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (313)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's49 (15.65)18.2507
2000's76 (24.28)29.6817
2010's153 (48.88)24.3611
2020's35 (11.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.28 (24.57)
Research Supply Index5.77 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.31%)5.53%
Reviews6 (1.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other313 (97.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]